Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabalumab in HLA-Presensitized ESRD Patients
NCT01200290Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2011
- Primary completion
- Mar 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tabalumab in end stage renal disease (ESRD), sponsored by Eli Lilly and Company. Started Apr 2011; status: completed.
02
Drugs
tabalumab
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT01200290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01200290.